<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04227171</url>
  </required_header>
  <id_info>
    <org_study_id>LG-FSOS002</org_study_id>
    <nct_id>NCT04227171</nct_id>
  </id_info>
  <brief_title>Observational Study to Develop Dosing Chart</brief_title>
  <official_title>A Multicenter, Prospective Cohort Observational Study to Develop Dosing Chart Based on Patient Specific Characteristics and Ovarian Response When Follitrope™ PFS is Administered Subcutaneously to Infertility Women Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Chem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Chem</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To confirm the predictors based on patient specific characteristics and ovarian response and
      develop dosing chart when Follitrope™ PFS is administered to infertility women patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Weeks</target_duration>
  <primary_outcome>
    <measure>No. of oocytes retrieved No. of oocytes retrieved Number of oocyte retrieved</measure>
    <time_frame>after OPU, normally 2 weeks</time_frame>
    <description>Number of oocyte identified by ovum pick up (OPU) after overovulation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oocyte maturity quality</measure>
    <time_frame>after OPU, normally 2 weeks</time_frame>
    <description>Metaphase II oocytes (%, ICSI only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total dose (IU) of Follitrope™ PFS administered</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total duration (days) of Follitrope™ PFS administered</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>E2 concentration on hCG day</measure>
    <time_frame>normally 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P4 concentration on hCG day</measure>
    <time_frame>normally 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertilization rate</measure>
    <time_frame>1~2 days after OPU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of embryo transferred</measure>
    <time_frame>3~5 days after OPU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>24 days after OPU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical pregnancy rate</measure>
    <time_frame>10 days after OPU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical pregnancy rate</measure>
    <time_frame>24 days after OPU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pregnancy rate</measure>
    <time_frame>up to 10 weeks after OPU</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Infertile Women Undergoing IVF or ICSI</condition>
  <arm_group>
    <arm_group_label>FSH only</arm_group_label>
    <description>GnRH agonist protocol &amp; GnRH antagonist protocol</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Infertile women undergoing In vitro fertilization(IVF) or Intracytoplasmic sperm injection
        (ICSI) for controlled ovarian stimulation
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female aged of 19 to 39 years

          -  Mean menstrual cycle in 25 to 35 days

          -  Patients to whom Follitrope PFS will be administered in those scheduled to undergo the
             IVF-ET according to the GnRH agonist or antagonist protocol

          -  In the past continuous IVF cycle failure less than 2 times

        Exclusion Criteria:

          -  Patients having a history of ovarian, breast, uterus, hyperthalamus, or pituitary
             tumor

          -  Abnormal uterine bleeding of undetermined origin

          -  Prior hypersensitivity to a component of recombinant FSH

          -  Ovarian cyst or enlargement of undetermined origin

          -  Clinically significant endocrine abnormalities

          -  Patients having polycystic ovary syndrome (PCOS) history

          -  Poor Ovarian responder (Bologna criteria)

          -  Patients who received Clomiphene citrate, Letrozole (Pemara), or Gonadotropin within
             30 days prior to enrollment in this study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>SO LA Park</last_name>
    <phone>+82-2-6987-4146</phone>
    <email>pphhoo@lgchem.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul Maria Fertility Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>So La Park</last_name>
      <phone>+82-2-6987-4146</phone>
      <email>pphhoo@lgchem.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 5, 2020</study_first_submitted>
  <study_first_submitted_qc>January 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>January 9, 2020</last_update_submitted>
  <last_update_submitted_qc>January 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

